Sanofi In Phase III Trials For Dengue Vaccine, Offering Emerging Market Potential
This article was originally published in PharmAsia News
Executive Summary
Sanofi already generates a substantial share of its revenue from emerging markets, but developing the first dengue vaccine would have significant impact on emerging market revenue, perhaps as early as 2015.